Skip to main content
Premium Trial:

Request an Annual Quote

Muses Labs Partners With Metabolon on Metabolomics of Cognitive Decline, Alzheimer's Disease

NEW YORK (GenomeWeb) – Muses Labs announced today that it has formed a partnership with Metabolon to research the metabolomics of pre- and early-symptomatic cognitive decline and Alzheimer's disease. 

Muses Labs currently markets a protocol called MEND for Alzheimer's disease, dementia, and related conditions. The methodology involves analyzing patients' genetic data and other medical information to identify the underlying pathways of their disorders and guide physician's treatment plans. 

Through its collaboration with Metabolon, Muses Labs said it plans to study metabolomics and apply it to the protocol, then develop and launch new clinical trial services this year. Specific terms of the arrangement were not disclosed.

"Metabolomics adds additional significant insight into a patient's biological status to improve identification of active pathologies and enable further refinement of patient care programs," Muses CEO Vik Chandra said in a statement. "Metabolomics has the potential to significantly expand the effectiveness of combination therapy protocols for Alzheimer's and other complex diseases."

Metabolon CEO John Ryals added that the partners aim to "use our proprietary technology in conjunction with Muses Labs' personalized protocols to provide clinicians with a more accurate health assessment of patients experiencing cognitive decline, as well as more actionable information."